Partnerships are essential to ensure better patient outcomes, and we are actively seeking to engage with companies and researchers who are developing these life-saving gene-modified cell therapy products. If you would like to learn more about working with Avectas and our technology, get in touch with us.
Avectas' Solupore® platform offers a cell engineering solution for next-generation cell therapies. Partnerships are essential to ensure better patient outcomes, and we are actively seeking to engage with companies and researchers who are developing these life-saving gene-modified cell therapy products. If you would like to learn more about working with Avectas, please get in touch with us.
Contact Us
This is the first study to successfully demonstrate the reprogramming of blood cell types using srRNA to produce functional iPSCs.
